CYCN · As filed with the SEC
Korsana Biosciences income statement, by fiscal year
The statement as Korsana Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations and Comprehensive Loss · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Revenues: | ||||
| Revenue from development agreement | — | — | 0 | 297,000 |
| Revenue from grants | — | — | — | 1,328,000 |
| Total revenues | 2,074,000 | 2,000,000 | 0 | 1,625,000 |
| Revenue from license agreement | 1,000,000 | 1,750,000 | — | — |
| Option to license revenue | — | 250,000 | — | — |
| Revenue from purchase agreement | 800,000 | — | — | — |
| Revenue from option agreement | 274,000 | — | — | — |
| Cost and expenses: | ||||
| Research and development | 959,000 | 286,000 | 1,515,000 | 31,493,000 |
| General and administrative | 6,088,000 | 5,342,000 | 8,132,000 | 14,504,000 |
| Loss on lease termination | — | — | — | 0 |
| Impairment loss | — | 0 | 3,304,000 | — |
| Total cost and expenses | 7,047,000 | 5,628,000 | 12,951,000 | 45,997,000 |
| Loss from operations | (4,973,000) | (3,628,000) | (12,951,000) | (44,372,000) |
| Gain on extinguishment of debt | — | — | — | 0 |
| Other income, net | ||||
| Interest income | 128,000 | 208,000 | — | — |
| Gain from settlement of account payable | 0 | 363,000 | — | — |
| Total other income, net | 1,445,000 | 571,000 | 358,000 | 294,000 |
| Net loss from continuing operations | — | (3,057,000) | (12,593,000) | — |
| Gain from discontinued operations | — | 0 | 7,330,000 | — |
| Gain from insurance recovery | 1,317,000 | — | — | — |
| Net loss | (3,528,000) | (3,057,000) | (5,263,000) | (44,078,000) |
| Net loss per share: | ||||
| Net loss per share from continuing operations - basic | — | (1.21) | (5.39) | — |
| Net gain per share from discontinued operations - baisc | — | 0 | 3.14 | — |
| Net loss per share - Basic | (1.11) | (1.21) | (2.25) | (1.01) |
| Net loss per share from continuing operations - diluted | — | (1.21) | (5.39) | — |
| Net gain per share from discontinued operations - diluted | — | 0 | 3.14 | — |
| Net loss per share - Diluted | (1.11) | (1.21) | (2.25) | (1.01) |
| Weighted average shares used in calculating: | ||||
| Basic shares | 3,181,000 | 2,518,000 | 2,338,000 | 43,469,000 |
| Diluted shares | 3,181,000 | 2,518,000 | 2,338,000 | 43,469,000 |
| Other comprehensive loss: | ||||
| Net loss | (3,528,000) | (3,057,000) | (5,263,000) | (44,078,000) |
| Other comprehensive loss: | ||||
| Foreign currency translation adjustment loss | 0 | (6,000) | 8,000 | 3,000 |
| Comprehensive loss | (3,528,000) | (3,063,000) | (5,255,000) | (44,075,000) |
| Revenue from license agreement | — | — | — | 0 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.